List view / Grid view
Acute Respiratory Distress Syndrome (ARDS)
David Vincent, Process Development Lead at eXmoor Pharma, details some of the critical steps that form the manufacturing strategy for providers of cell and gene therapies.
In this article, EPR’s Hannah Balfour explores the current usage of monoclonal antibody therapies for COVID-19, with commentary from Professor Adrian Streinu-Cercel of the Carol Davila University of Medicine and Pharmacy.
JadiCell™ was shown to significantly improve survival in COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS) and also reduce lung scarring associated with long-COVID-19.
Vaccine-induced prothrombotic immune thrombocytopenia: pathogenetic and epidemiological issues of concern
Giovanni Di Guardo, DVM, Dipl. ECVP, retired Veterinary Pathologist, discusses the association between adenoviral vector COVID-19 vaccines and rare blood clots, outlining four areas warranting further research.
New data shows patients with COVID-19-related Acute Respiratory Distress Syndrome (ARDS) were up to 75 percent less likely to die when treated with remestemcel-L and dexamethasone.
The trial will evaluate whether the novel IC14 anti-CD14 antibody can reduce recovery time and severity of COVID-19 symptoms in hospitalised patients.
In the trial Leukine® (sargramostim, rhuGM-CSF) improved oxygenation in COVID-19 patients with acute respiratory failure by at least a third in over half of those treated.
In a Phase IIb trial, hospitalised COVID-19 patients treated with desidustat did not develop acute respiratory distress syndrome (ARDS).
Interim data from 1,000 hospitalised patients with moderate COVID-19 symptoms shows that full doses of heparin can improve patient outcomes and could reduce ICU burden.
The trial will primarily assess whether alisporivir (Debio 025) can significantly reduce COVID-19 viral load in hospitalised COVID-19 patients with moderate symptoms.
The designation should expedite the review of remestemcel-L, a cellular therapy that has shown promise in treating acute respiratory distress syndrome (ARDS) in COVID-19 patients.
The fourth iteration of the COVID-19 treatment trial will determine whether remdesivir plus baricitinib or dexamethasone is more effective at promoting recovery from COVID-19.
The trial’s independent Data Safety Monitoring Board (DSMB) recommended that the Phase III study evaluating remestemcel-L continue based on the second interim analysis.
NoveCite has an exclusive licence to develop and commercialise mesenchymal stem cell therapies to treat acute respiratory conditions such as Acute Respiratory Distress Syndrome (ARDS).